Podcasts about Skin cancer

An investigation by consumer group Choice has found that several leading Australian sunscreens don't provide the level of protection they say they do. The findings, which have been disputed by manufacturers, have raised questions about the testing and regulations of sunscreens in Australia. Consumer affairs reporter Catie Mcleod tells Nour Haydar why questions are being asked about the claims made by some brands and what consumers need to know now

I'm joined by Susanna Daniels, CEO of Melanoma Focus, and horticulturists Rachel Reynolds, Paul Kimberley and Jenny Warner, who share their personal experiences with skin cancer. With temperatures on the rise, we explore why sun safety is essential for anyone working outdoors, how to protect yourself effectively, and the serious risks of not taking the sun seriously. Links Melanoma Focus is a national charity dedicated to providing help and support to melanoma patients and healthcare professionals as well as raising awareness of melanoma, the 5th most common cancer in the UK.  As nearly 9 in 10 melanomas are preventable, awareness and advocacy work is key element of the work.  Melanoma awareness posters and a comms toolkit (including a specific farming and horticultural comms toolkit) is available via our melanoma awareness page. Some other useful pages: What is melanoma  Sun safety Signs and symptoms of melanoma  How to check your skin and nails How a melanoma is diagnosed The Melanoma Helpline – expert skin cancer nurses are available for anyone with a worry about melanoma from diagnosis to treatment and beyond Melanoma Stages and Treatment – Patient Guide    Please support the podcast on Patreon

00:38 — Introducing Kim Stainton and her extraordinary healing journey01:37 — Discovering skin cancer on her chest and face, and early attempts at treatment03:00 — Why Kim turned to cannabis oil and how she learned to make it06:00 — Treating her facial cancers with oil (topically and orally)07:50 — Giving cannabis oil to her mother with Alzheimer's, and the clash with social services11:35 — Improvements in her mother's health and quality of life13:00 — The personal cost: losing contact with her daughter13:30 — Ian's own experience using cannabis oil for a facial melanoma16:25 — Why skin cancer often looks worse before it heals with cannabis oil17:15 — Kim's journey with a misdiagnosed tumor on her hand21:00 — Topical blends Kim uses and how her tumor is shrinking22:50 — Stage 4 colon cancer diagnosis and the emotional cause behind it28:00 — How mindset shift played a role in her healing30:00 — Stories of others Kim has helped through cannabis medicine33:35 — The importance of quality of life, even in terminal cases34:50 — On living without fear of authorities36:00 — Working through personal traumas and inner healing37:45 — Plans for a future episode on making cannabis oil and advanced treatments Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

The detection of melanoma and a range of other skin diseases could become faster and more accurate with a new AI powered tool 

Yankees offering free skin cancer screening To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Most sport takes place outdoors, and with growing concerns around sun exposure, active people are at a higher risk of developing skin cancer than most. Dr Dagmar Whitaker, vice president of the World Melanoma Society and one of the leading authorities on the subject, breaks down the current trends, explains which countries present a higher risk, the most effective ways to prevent skin cancer (hint: you smear it on from a young age!) and the breakthrough treatments that are not yet available. Whitaker is also president of the Melanoma Society South Africa and Immediate Past President of the Dermatological Society South AfricaSupport The Real Science of Sport on DiscourseDiscourse is our VIP community, where listeners gather around to chat more about the topics we cover on the show, the sports news, and anything else that has grabbed their sports science attention. If you want to be part of that community, and get way more value from The Real Science of Sport, you join by becoming a Patron on the show for a small monthly donation! We hope you'll support the show, and join the Sports science conversation! Hosted on Acast. See acast.com/privacy for more information.

Did you know that skin is the largest organ in the body? Too often we may take it for granted, but skin cancer can be devastating when it goes unnoticed.Which raises a few questions, like what factors increase the risk of skin cancer? And, which skin cancers are the worst? If a big defect is left after surgery, how can an area like a nose, lip, or eyelid be reconstructed? What about scar?Plastic surgeon Dr. Joseph Spaniol provides answers, and he also has some wise words both for detection of skin cancer and prevention.Let's listen in, now...

Gugs’ Mhlungu speaks to Dr Fundile Nyati, Resident GP and CEO of Proactive Health Solution, discussing the high risk of skin cancer faced by those with albinism, as well as the barriers to sunscreen access, protective gear, and life-saving skin cancer screenings. 702 Weekend Breakfast with Gugs Mhlungu is broadcast on 702, a Johannesburg based talk radio station, on Saturdays and Sundays Gugs Mhlungu gets you ready for the weekend each Saturday and Sunday morning on 702. She is your weekend wake-up companion, with all you need to know for your weekend. The topics Gugs covers range from lifestyle, family, health, and fitness to books, motoring, cooking, culture, and what is happening on the weekend in 702land. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Radiation for skin cancer - with Dr. Jacob Scott! -Lipedema - not just for social media (?) - Inebilizumab for IgG4 disease -HTN and PWS -Learn more about radiation therapy and other non-surgical options for skin cancer treatment at The Dermatology Association of Radiation Therapy: https://dermassociationrt.org/Join Luke's CME experience on Jak inhibitors! ⁠rushu.gathered.com/invite/ELe31Enb69⁠Learn more about the U of U Dermatology ECHO model!https://physicians.utah.edu/echo/dermatology-primarycare#:~:text=ECHO%20Model,being%20presented%20in%20the%20session.Want to donate to the cause? Do so here!Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠Check out our video content on YouTube:⁠www.youtube.com/@dermaspherepodcast⁠and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠The University of Utah's DermatologyECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -⁠ Connect with us!- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠- Check out Luke and Michelle's other podcast,SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out ourfriends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learnmore dermatology!

See omnystudio.com/listener for privacy information.

Can your gut health affect your skin—and even your risk of cancer?   After years of struggling with debilitating gut issues and extreme weight loss, Chuck Carroll is now facing a new health challenge: skin cancer. Could these be connected?   In this powerful and deeply personal episode, Chuck sits down with leading gastroenterologist and gut health expert Dr. Will Bulsiewicz to explore the latest science linking gut health, skin conditions, and cancer risk.   In this episode you'll learn about: - Chuck's new cancer diagnosis and how he's doing - The gut-skin connection - How gut issues and skin cancer could be connected - What your skin could be telling you about your gut health - What comes next for Chuck in his healing journey   Subscribe to The Exam Room for more science-back nutrition advice, health tips and incredible stories of transformation and healing.   This episode of The Exam Room is powered by Dr. Brooke Bussard and the Eat and Feel Good course to achieve optimal health.   — — SHOW LINKS — — Dr. Will Bulsiewicz Books: https://amzn.to/3HowGBL Courses: https://theplantfedgut.com 38Tera: https://38tera.com Instagram: https://www.instagram.com/theguthealthmd — — — Dr. Brooke Bussard Website: https://drbrookebussard.com — — EVENTS — — NHA Conference Where: Cleveland, OH When: June 26-29, 2025 Tix & Speakers: https://bit.ly/NHAtix2025 20% off virtual tickets with code: PCRM20 $100 off in-person tickets with code: PCRM100 — — — International Conference on Nutrition in Medicine Where: Washington, DC When: August 14-16, 2025 Tix & Speakers: https://www.pcrm.org/icnm — — BECOME AN EXAM ROOM VIP — — Sign up: https://www.pcrm.org/examroomvip — — THIS IS US — — The Exam Room Podcast Instagram: https://www.instagram.com/theexamroompodcast — — — Chuck Carroll Instagram: https://www.instagram.com/ChuckCarrollWLC Facebook: https://www.facebook.com/ChuckCarrollWLC X: https://www.twitter.com/ChuckCarrollWLC — — — Physicians Committee Instagram: https://www.instagram.com/physicianscommittee Facebook: https://www.facebook.com/PCRM.org X: https://www.twitter.com/pcrm YouTube: https://www.youtube.com/user/PCRM Jobs: https://www.pcrm.org/careers — — SUBSCRIBE & SHARE — — 5-Star Success: Share Your Story Apple: https://apple.co/2JXBkpy​​ Spotify: https://spoti.fi/2pMLoY3 — — — Please subscribe and give the show a 5-star rating on Apple Podcasts, Spotify, or many other podcast providers. Don't forget to share it with a friend for inspiration!

Dr. Jack Stockwell (www.forbiddendoctor.com & www.jackstockwell.com | Phone: 866-867-5070), a GAPS Practitioner and NUCCA Chiropractor, discusses the biggest concerns for health and medical news from a natural position over a Western Medicine approach. He starts today's episode with the idea that the sun does not cause skin cancer, rather exposes the weaknesses in your skin due to poor dietary choices that can lead different growths on the skin, and why he opposes sunblock as it pertains to blocking a natural process exposure to the sun and stopping vitamin D absorption as well as other helpful nutrients we can get from the sun — not to mention the harmful chemicals in most sunscreens. Next up, the myth that breakfast is the most important meal of the day and at what time you should start eating during your day, questioning when food is not food, the viral recipe video that left Dr. Jack feeling dumbfounded, and who/what the forbidden doctor really is. Then, Dr. Jack discusses an increase of young asthma sufferers, that more children are being diagnosed with ADHD or autism, a fight against breakfast cereals, and why “eating healthy” isn't always healthy eating. To round out the conversation, Doug and Dr. Jack break down what makes us feel stressed, what stress does to our bodies, and how to fight stress and keep a calmer mind. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers - New Treatment Approaches - Emerging Role of Targeted Therapy - Clinical Trial Updates - Managing Treatment Side Effects, Discomfort & Pain - Tips for Caring for Your Skin During Cancer Treatments - Sun & Wind Safety Tips - Communicating with Your Health Care Team About Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers - New Treatment Approaches - Emerging Role of Targeted Therapy - Clinical Trial Updates - Managing Treatment Side Effects, Discomfort & Pain - Tips for Caring for Your Skin During Cancer Treatments - Sun & Wind Safety Tips - Communicating with Your Health Care Team About Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers - New Treatment Approaches - Emerging Role of Targeted Therapy - Clinical Trial Updates - Managing Treatment Side Effects, Discomfort & Pain - Tips for Caring for Your Skin During Cancer Treatments - Sun & Wind Safety Tips - Communicating with Your Health Care Team About Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers - New Treatment Approaches - Emerging Role of Targeted Therapy - Clinical Trial Updates - Managing Treatment Side Effects, Discomfort & Pain - Tips for Caring for Your Skin During Cancer Treatments - Sun & Wind Safety Tips - Communicating with Your Health Care Team About Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers - New Treatment Approaches - Emerging Role of Targeted Therapy - Clinical Trial Updates - Managing Treatment Side Effects, Discomfort & Pain - Tips for Caring for Your Skin During Cancer Treatments - Sun & Wind Safety Tips - Communicating with Your Health Care Team About Quality-of-Life Concerns - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

Today, I'm joined by Teo Soleymani, MD—a double board-certified dermatologist, fellowship-trained Mohs and facial reconstructive surgeon, and an expert in all things skin cancer—plus, he's as entertaining as he is knowledgeable. If you've ever wondered whether you should slather on sunscreen religiously, or if embracing more sunlight is actually good for you, we're here to offer the clarity and nuance that's so often missing from the conversation. Listeners of this podcast can receive 15% off of SunPowder when you go to sunpowder.co/discount/NAT15 (it's .co not .com or else you won't find it).   What we discuss: Sun exposure: fear vs. benefits debate ... 00:06:38 Genetics vs. sun in driving skin cancer risk ... 00:09:04 Types of skin cancer explained ... 00:10:38 HPV, environmental toxins, and non-UV causes ... 00:22:35 Burning vs. safe sun—practical advice ... 00:21:24 Sunscreen: mineral vs. chemical, what matters ... 00:36:01 Problems with spray sunscreens ... 00:40:45 Melanin, UV damage, and skin aging ... 00:13:40 Melasma: hormones and stubborn pigmentation ... 00:47:19 Estrogen, collagen, and topical supplements ... 00:49:18 Astaxanthin and polypodium—internal sun protection ... 00:56:01 Nicotinamide: strong evidence for cancer prevention ... 01:04:11 Sunpowder supplement: trials and benefits ... 01:07:43 Laser resurfacing and reduced cancer risk ... 01:12:33 Genetics, immune health, and testing limits ... 01:15:31 Where to find Sunpowder + connect with Teo ... 01:18:53   Our Amazing Sponsors: LVLUP - Neuro Re-Generate the world's first liposomal triple peptide formula, designed to support mental clarity, focus, and overall brain health. Visit www.lvluphealth.com and use code NAT for 20% off your order. Qualia - Senolytic - Clinically tested formula with 9 plant-based, vegan ingredients designed to help your body clear out zombie cells—so you can feel younger, faster. Visit qualialife.com/nathalie and use promo code NATHALIE to save 15% Young Goose L.A.D.R. Serum -  Powered by light-activated DNA repair enzymes, NAD+, and collagen peptides, it reverses damage while you go about your life. Sunlight? Red light therapy? It all helps this serum work smarter, not harder. Visit YoungGoose.com—use code NAT10 to get started, or 5NAT if you're an existing customer. Future-proof your face.   More from Nat:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group   More from Teo Soleymani: Website: www.californiadermatology.com and https://sunpowder.co/discount/NAT15 Instagram: @teosoleymanimd Instagram: @drinksunpowder  

This week's Addicted to Fitness describes they best way to protect yourself from the sun's harmful rays. Nick and Shannon discuss the prevelance of skin cancer in the United States, the information your iPhone can give you about sun protection, and what ingredients you should avoid when purchasing your sunscreen. Follow the podcast profile on Instagram @TheATFPodcast. Give it a listen and let us know what you think by leaving a rating & review in Apple Podcasts. Visit addictedtofitness.libsyn.com to listen to our entire archive. Like & Follow the Addicted to Fitness Podcast Facebook page (Facebook.com/addictedtofitnesspodcast). Follow Nick & Elemental Training Tampa on Facebook (www.facebook.com/ElementalTampa) and Instagram (www.instagram.com/ettampa/) to participate in free live workouts. Follow the podcast profile on Instagram @TheATFPodcast and send Nick a DM if you're interested in receiving a customized workout plan or visit shannonjb.com to learn more about Shannon's wellness coaching program.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We dive deep into the essential topic of skin cancer prevention and sun protection methods. As summer approaches, it's crucial to understand how to protect yourself from harmful UV rays that can lead to skin cancer, a condition that affects one in five Americans in their lifetime.• One in five Americans will develop skin cancer in their lifetime• Seek shade between 10am-2pm when the sun's rays are strongest• Wear protective clothing including lightweight long sleeves, pants, and wide-brimmed hats• Choose broad-spectrum, SPF 30+ water-resistant sunscreen• Apply one ounce (a shot glass amount) to cover an adult body• Reapply sunscreen every two hours or after swimming/sweating• SPF 30 blocks 97% of UVB rays, but no sunscreen blocks 100% of rays• Babies under six months should avoid sun exposure completely• For sunburns: stay indoors, keep skin moisturized, drink extra water, and don't pop blistersShare this episode with anyone who spends time in the sun. Check us out on Instagram, visit our website for all our old episodes, or sign up for our email list in the description wherever you listen to podcasts.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

This week, Bobbi Conner talks with MUSC's Dr. Jane Scribner about sun protection strategies to reduce the risk of skin cancer.

In this episode of Feel Better, Feel Great, Dr. Andrea McSwain explores the deeper layers of skin cancer, toxic burden, and the powerful connection between your internal health and skin. Learn how to identify the three main types of skin cancer—basal cell, squamous cell, and melanoma—while discovering how detox pathways, inflammation, oxidative stress, and conventional skincare products contribute to skin damage. Packed with holistic prevention strategies like clean beauty swaps, anti-inflammatory nutrition, natural sun protection, and daily detox support, this episode empowers you to protect your skin from the inside out. Tune in to decode your body's signals, reduce your toxic load, and embrace radiant, resilient skin. #skincancerawareness #HolisticSkincare #DetoxYourSkin #FunctionalMedicine #NaturalHealth #OxidativeStress #ToxicBurden #CleanBeauty #AntiInflammatoryLifestyle

Johann Ilgenfritz's life changed in 2011 when he had a heart attack and six months later was diagnosed with cancer. After unsuccessful Radio Therapy he researched for a cure, soon realizing that that there was no central point for reliable online health information. He decided to create a platform and launched UK Health Radio, while still fighting cancer. After overcoming cancer through nutritional and lifestyle changes, he earned the title "The Curator of Health Expertise" from the press. His guiding principle is simple: "Good health is a choice." Initially, he saw cancer as the root of his illness but later realized it was merely a symptom of an already unwell body. He understood that by addressing the underlying cause, he could transform the outcome. With this vision, UK Health Radio (https://ukhealthradio.com/) has embraced a clear mission: to inspire and empower people to take responsibility for their own health. This does not mean taking your health into your own hands, but to be part of the process of attaining and/or keeping your health freedom. It is all about being informed, being empowered, taking action and being healthy! UK Health Radio delivers information through 41 shows airing 24/7, reaching over 1.5 million very dedicated listeners and is now also available on 11 podcast platforms worldwide. In February of 2024, Johann created The Alkaline Collective Mastermind (https://alkaline-collective.com/), a dedicated online community for those battling cancer, aiming to prevent it, or striving to stop it's recurrence. Designed for individuals who are committed to hold themselves accountable, and seek a comprehensive toolbox of resources.

May is Skin Safety Awareness Month. How should Las Vegas protect themselves from harmful UV rays and skin cancer?

Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.

In this episode, Therese Markow and Dr. Deborah Lang discuss the rise of skin cancer, particularly melanoma, and its causes. Dr. Lang explains that skin cancers are derived from different skin cells: basal cell carcinoma and squamous cell carcinoma, both linked to UV exposure, and melanoma, which can be UV-independent and linked to genetic susceptibility. Dr. Lang emphasizes the importance of early detection and personalized medicine, noting that melanoma can metastasize early. She also highlights the role of genetic mutations in cancer development and the impact of funding cuts on cancer research.    Key Takeaways: There are three major types of skin cancer. About 80% are basal cell carcinomas.  Because we are living longer, we have an increased chance of cancer. However, other reasons for increased skin cancer include increased UV exposure and tanning beds.  We are all born with moles, but if you notice a change or have a lot (such as over 100), it is worth getting them checked out.  Between 5 and 25 minutes of sun exposure per day is enough for your vitamin D production (less for lighter skin). However, sunlight has other benefits for your health and circadian rhythm.    "Melanomas are derived from a different type of cell - from cells that produce pigment called melanocytes. While this type of cancer is much rarer than basal cell carcinoma or squamous cell carcinoma, it is the most lethal type of skin cancer." —  Dr. Deborah Lang   Episode References:  NIH: https://www.nih.gov/  American Cancer Society: https://www.cancer.gov/  Leo Foundation: https://leo-foundation.org/en/    Connect with Dr. Deborah Lang: Professional Bio: https://profiles.bu.edu/Deborah.Lang  LinkedIn: https://www.linkedin.com/in/deborah-lang-691158208/  ResearchGate: https://www.researchgate.net/scientific-contributions/Deborah-Lang-38651370    Connect with Therese: Website: www.criticallyspeaking.net Threads: @critically_speaking Email: theresemarkow@criticallyspeaking.net   Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.  

Skin cancer is very common among men and women. LaKimerly Coates, MD, a Board Certified Dermatologist, discusses signs and symptoms of skin cancer as well as how to reduce risk.

Navigating the intricate landscape of medical technology often involves overcoming substantial challenges, not just in device innovation but also in ensuring successful integration into healthcare systems. One significant hurdle is the adoption of new technologies by general practitioners, who require tools that are both effective and easy to integrate into their existing workflows without the complexities of specialist equipment. In this week's episode, sponsored by Physician Growth Accelerator, we are joined by Cody Simmons, co-founder and CEO of DermaSensor. Cody discusses DermaSensor, a revolutionary device that simplifies skin cancer detection, enabling general practitioners to diagnose with the accuracy of dermatologists. We delve into the story of DermaSensor, from its initial conception to achieving FDA clearance and the challenges faced in bringing this innovative technology to market. What we discuss in the episode: The development of DermaSensor and its impact on simplifying skin cancer detection for non-specialists. The barriers to technology adoption in healthcare, particularly issues around reimbursement and system integration. Strategies employed by DermaSensor to navigate regulatory hurdles and market challenges. Real-world benefits of the device in improving diagnostic accuracy and reducing healthcare inefficiencies. Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator DermaSensor Social Media:  Connect with Cody on LinkedIn Connect with Zed on LinkedIn

Last month, Afternoons met Jessica, a new mum who leapt into action to help her 'agency' cleaner, after discovering she - and her colleagues - had been denied healthcare, visas and access to their passports. Having worked with Dubai Police to get the team's documents returned to them, Jessica set about helping them with their CVs to find them better employment - but as she explains to Helen today, she ended up hiring them instead. Plus, lawyer Dilini Loku joins us for an employment clinic, Dr Bisi Laniyan explains why stress is not a flex, we talk mole mapping for kids with dermatologist Dr Parul Thakur, and Haus & Haus' Harrison Rackham Beadle is on hand to handle your property questions.See omnystudio.com/listener for privacy information.

Khloe Kardashian Shares Horrifying Photos After Having A TUMOR Removed From Her Face Following Skin Cancer ScareAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

From the invisible impact of concussions in sports to the overlooked threat of skin cancer from sun exposure, Dr. Joe Sirven dives into hidden dangers that can change lives in an instant.

This week on Death Clock, Brant speaks with Dr. Anna Pavlick, a leading oncologist at Weill Cornell, to break down everything you need to know about skin cancer — from prevention to treatment. They cover the three most common types of skin cancer (basal cell, squamous cell, and melanoma), why early detection is critical, and what to actually look for when checking your skin. Dr. Pavlick shares actionable advice on how simple habits like wearing sunscreen, avoiding tanning beds, and regular dermatologist visits can make a life-saving difference. They also explore the latest advancements in skin cancer treatment, including the rise of immunotherapy and promising new research using AI and cellular therapies. This episode is a must-listen for people of all demographics. Hope you enjoy.

Dr Beibei Du Harpur & Kathryn Clifford from Skin Cancer charity SKCIN tell us we need to know about Skin Cancer Awareness Month.Footballer legend Graeme Souness, speaks to us live from the English Channel as he swims to France and back, raising money for the charity, DEBRA.Join Chris, Vassos and the Class Behind The Glass every morning from 6.30am for laughs with the listeners and the greatest guests. Listen on your smart speaker, just say: "Play Virgin Radio." Hosted on Acast. See acast.com/privacy for more information.

Novelist Claire Cameron investigates the shocking true story of a couple killed by a black bear in Ontario's Algonquin Provincial Park in her debut memoir "How to Survive a Bear Attack." Why did this tragedy resonate with her? And what answers did she hope to find in her quest? Claire Cameron joins Nam Kiwanuka to discuss her latest book. See omnystudio.com/listener for privacy information.

Today on the radio show. 1 - Smoko chat. Shaq. 6 - Weekend of sport 9 - Jon breaks bad news. 11 - Long weekend funny. Camping test. 15 - Cow vs Boat. 19 - Skin Cancer soap. 23 - Man gives tree a voice. 26 - Bin Laden Sledge hammer. 30 - What cool gifts have you been given? 35 - Pete Bethune Billionaires dog. 38 - Long weekend funny. Dutch Barn ad. 40 - Late mail. 43 - Last drinks. Get in touch with us: https://linktr.ee/therockdrive

According to the American Cancer Society, approximately 5-and-a-half million cases of non-melanoma skin cancer are diagnosed each year in the US. Many of those cancers are highly preventable. In addition, though, about 100 thousand news cases of melanoma are diagnosed each year, making skin cancer the most common cancer in the US.  Dr. Jeanine Cook-Garard talks with Dr. Bhuvanesh Singh, surgical director of the Skin Cancer Program at the Northwell Health Cancer Institute. A board-certified otolaryngologist and head and neck surgeon with extensive experience in oncological and reconstructive surgery, Dr. Singh has published over 190 articles in major journals, is a co-editor of two medical textbooks, and has received numerous research grants.

Getting outdoors into the sun is healthy, but when is it too much and are we putting our skin at risk if we don't protect it? Today's episode I dive into skin cancer with skin cancer surgeon and dermatologist Dr. Ellen Marmur. We cover: Different types of skin cancers and what to look out for How to screen for skin cancer If you need surgery and if so, how best to remove skin cancers What those white freckles on your legs really mean Where skin cancers show up most for women in midlife Photobiomodulation – light therapy can be used for skin cancer treatment and prevention Lasers How best to protect your skin Is sunscreen toxic and what to look out for when buying, plus what she uses The best and worst times to spend time outdoors Should we really be skipping the sunglasses to set our circadian rhythm? The coolest light device for skin treatment, even cancer, and protection   Dr. Ellen Marmur is one of New York City's most respected dermatologists, known for her unique combination of expertise in skin cancer surgery and cosmetic dermatology. After eight years as the first woman Chief of Dermatologic Surgery at Mount Sinai Medical Center, Dr. Ellen founded Marmur Medical, where she has spent the past decade pioneering advanced treatments in skin cancer, Mohs surgery, reconstructive surgery, women's health dermatology, and aesthetic procedures. Dr. Marmur has done pioneering research in green LED light therapy, in collaboration with Rockefeller University. Dr. Marmur is a full Clinical Professor of Dermatology at Mount Sinai Medical Center, where she trains the next generation of dermatologists.  Get 15% off the MMSphere and other products on the Marmur Medical website and MMSkincare.com with code ZORA or this link https://mmskincare.com/zorab Website: https://www.marmurmedical.com Website: https://mmskincare.com/ Contact Dr. Ellen Marmur Instagram: https://www.instagram.com/dr_ellen_marmur Instagram: https://instagram.com/mmskincare  TikTok: https://tiktok.com/@dr.ellenmarmur  TikTok: https://tiktok.com/@mmskincaregenius  TikTok: https://tiktok.com/@marmurmedical   Give thanks to our sponsors: Qualia senolytics and brain supplements. 15% off with code ZORA here.  Try BEAM minerals at 20% off with code ZORA here. Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Get Mitopure Urolithin A by Timeline. 10% discount with code ZORA at  Get Magnesium Breakthrough by Bioptimizers. 10% discount with code HACKMYAGE at  Try OneSkin skincare with code ZORA for 15% off https://shareasale.com/r.cfm?b=2685556&u=4476154&m=102446&urllink=&afftrack= Join ⁠⁠⁠Biohacking Menopause⁠⁠⁠ before May 1, 2025 to win a bottle of Accelerated Health iodine and Essential Amino Acids! 10% off with code ZORA at AcceleratedHealth.com   Join the Hack My Age community on: Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠  Private Women's Only Support Group: https://hackmyage.com/biohacking-menopause-membership/ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠   

Imagine your doctor could precisely predict your personal risk of disease, diagnose the cause of illness with pinpoint accuracy when it did occur, and develop an effective treatment plan with low side effects the first time, rather than through trial and error. That's the promise of personalized medicine. And it would be a revolution in healthcare. At the heart of this vision is the notion that our genetic differences have a big impact on how each of us responds to disease and treatment. To realize a future of personalized medicine then, we need to understand and investigate just how genetic variations, including mutations, contribute to illness and respond to doctors' attempts to address it. But how can scientists do that efficiently with a human genome that spans about three billion base pairs of DNA across tens of thousands of genes? That's where the work of PhD student Dawn Chen comes in. A student in Harvard's Department of Stem Cell and Regenerative Biology and the Systems, Synthetic, and Quantitative Biology Program, Chen was named a recipient of the 2025 Harold M. Weintraub Graduate Student Award for Outstanding Achievement and Exceptional Research in the Biological Sciences, presented by Seattle's Fred Hutch Cancer Center. With her colleagues in the lab of Harvard professor Fei Chen, Dawn Chen is developing an innovative gene-editing tool known as helicase-assisted continuous editing, or HACE. A breakthrough in genetic engineering, supported in part by funds from the National Institutes of Health, HACE makes edits to specific genes, allowing researchers to investigate how genetic variations contribute to disease. The technique could lead to the identification of specific mutations that influence the effectiveness of drugs and therapies for illnesses like cancer. 

Professor Deirdre Murray, National Cancer Registry Director, explains the improvements made in skin cancer survival rates and the importance of skin cancer awareness

Join me for an important discussion with Jonathan Otto. To learn more about Red Light Therapy visit https://myredlight.com and use promo code SETH to save an additional 10% Forbidden Health book (free): https://jiii.io/qfmz3b To learn more about investing in gold & silver visit - http://goldwithseth.com, or call 626-654-1906 For high quality storable foods and seeds, visit http://heavensharvest.com and use promo code SETH to save 15% on your order. Kimchi One from Brightcore – Improve your health, improve your life. 25% Off with code: MANINAMERICA at https://mybrightcore.com/maninamerica Or dial (888) 575-6488 for up to 50% OFF and Free Shipping – ONLY when you call!See omnystudio.com/listener for privacy information.

U.S. drops to lowest-ever standings in “World Happiness Report”; Bergamot notches double-digit cholesterol improvements in new study; Benefits of collagen peptides; Addressing post-chemotherapy fatigue; Solutions for knee pain; Tattoos linked to skin cancer, lymphoma risk; High-dose vitamin D slows progression of MS; Advances in AI lead to smart prosthetics, brain control of robot arms for paralytics. 

Send us a textIn this episode, I'm joined by Leah Koskinen from Make Derm Sure, a passionate skin cancer advocate. Leah shares her story of being diagnosed with stage 3 melanoma at just 26 years old. As a young mother, she faced challenging decisions about her health and healing journey.We dive into:☀️ Common misconceptions about skin cancer☀️ The importance of SPF and how to choose the right one☀️ Easy ways to protect your skin and your family's skin every dayIf you're passionate about skincare, prevention, and overall wellness, this episode is packed with valuable insights you won't want to miss.Links & Resources:

Two members of Congress have introduced legislation that would cut back on state and federal emission regulations on large trucks. Also, a former trucker has created a product to protect you from something virtually every trucker faces – damage to their left arm from the sun. And among the many complex things about running a trucking business is IFTA taxes – and if you don't do it right, you could face an audit. 0:00 – Newscast 10:01– Product designed to combat the ‘trucker tan' 24:27 – How to avoid – or survive – an IFTA audit 39:25 – Congress acts to stop overzealous emission rules

We discuss the profound effects of light on health, specifically the role of sunlight in energy production within the body. We also cover the evolutionary significance of light exposure, the mechanisms by which different wavelengths of light interact with biological systems, and the implications for health and disease, particularly cancer. Cameron Borg is a qualified nutritionist, practicing pulmonary scientist, podcaster and health coach from Sydney, Australia. He hosts the Ricci Flow Nutrition Podcast, interviewing world leaders including Gerald Pollack, Stephanie Senneff, Scott Zimmerman and more. He is a leader in applied circadian and quantum biology in Australia. Attend REGENERATE Health summit March 22nd in SYDNEY & March 23rd in Melbourne - https://www.regenerateaus.com/SUPPORT the Regenerative Health Podcast by purchasing through the following links: 

Native Americans have a lower risk of developing skin cancer than their white counterparts. But a more comprehensive look at the disease over ten years' time shows gaps in how skin cancer among Native people is counted. It also signals problems in awareness, diagnosis, and treatment among people who live in poverty or in rural areas. We'll look at the links between Native Americans and skin cancer, and get a reminder about what to look for. GUESTS Dr. Anna Chacon (Maya), board certified dermatologist Dr. Rachel Asiniwasis (Plains Cree and Saulteaux First Nations), dermatologist and clinician researcher Melissa Buffalo (Meskwaki Nation), Chief Executive Officer at American Indian Cancer Foundation

Brandi Corbello is the founder and CEO of Melan, a sunscreen brand redefining sun care with a focus on comfort, fun, and giving back to melanoma and skin cancer research. As a melanoma survivor, Brandi's journey inspired her to create a clean, effective sunscreen that makes sun protection effortless and enjoyable.After facing her own battle with skin cancer, Brandi launched Melan with a mission to change the way people think about sunscreen. Under her leadership, Melan has combined high-performance formulas with transparency and purpose, ensuring that every product not only protects but also supports melanoma awareness and research. A passionate advocate for self-care, wellness, and community, Brandi continues to push the boundaries of the sun care industry, making sunscreen a daily essential for all.In This Conversation We Discuss:[00:45] Intro[01:07] Advocating for better product standards[05:17] Investing in product education before launching[06:54] Researching before committing to a business[07:36] Defining brand identity before launch[09:00] Launching new products based on demand[10:28] Using trade shows for brand awareness[11:29] Episode Sponsors: StoreTester and Intelligems[14:41] Learning the complexities of retail barcodes[16:57] Testing the new brand with customers[19:11] Building community through live eventsResources:Subscribe to Honest Ecommerce on YoutubeMelan | Protect Your Rind melansuncare.com/Follow Brandi Corbello linkedin.com/in/brandicorbelloBook a demo today at https://www.intelligems.io/Done-for-you conversion rate optimization service https://storetester.com/If you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

#804: Join us as we sit down with Teddi Mellencamp – reality TV star, entrepreneur, & accountability coach. From her early days navigating Hollywood to starring in Bravo's hit show, The Real Housewives of Beverly Hills, Teddi is no stranger to the spotlight. In this episode, Teddi opens up about the realities of reality TV, the evolution of relationships through life's seasons, her personal battle with melanoma, & how embracing accountability became the key to her success!   To Watch the Show click HERE   For Detailed Show Notes visit TSCPODCAST.COM   To connect with Teddi Mellencamp click HERE   To connect with Lauryn Bosstick click HERE   To connect with Michael Bosstick click HERE   Read More on The Skinny Confidential HERE   To Call the Him & Her Hotline call: 1-833-SKINNYS (754-6697)   To learn more about Teddi's Accountability Coaching visit allinbyteddi.com and mention The Skinny Confidential on your application form for 15% off.    This episode is brought to you by The Skinny Confidential   Head to the HIM & HER Show ShopMy page HERE and LTK page HERE to find all of Michael and Lauryn's favorite products mentioned on their latest episodes.   This episode is sponsored by The Skinny Confidential   Optimize your daily beauty routine. Shop Beauty Water at ShopSkinnyConfidential.com.    This episode is sponsored by Chomps   Get 15% off your order of Chomps meat sticks at Chomps.com/SKINNY with code SKINNY.    This episode is sponsored by Arrae    Go to arrae.com and use code 'SKINNY' at checkout to receive 15% off and 4 free Bloat travel packs with your first purchase or autoship order.   This episode is sponsored by DailyLook   Head to DailyLook.com to take your style quiz and use code SKINNY for 50% off your first order.   This episode is sponsored by Momentous   Go to livemomentous.com/skinny and try it today at 20% off with code SKINNY, and start living on purpose.   This episode is sponsored by OpenPhone   Right now, OpenPhone is offering 20% off of your first 6 months when you go to OpenPhone.com/skinny.   This episode is sponsored by ShipSkis   Go to Shipskis.com and use the code SKINNY to get 20% off your first shipment and save yourself the hassle this ski season. Produced by Dear Media

A look at supplements and low-fat diets